Charles River Laboratories International, Inc. · NYSE:CRL

Charles River Laboratories International — Q2 2022 Earnings Presentation

12 slides from Charles River Laboratories International's earnings presentation, Jun 25, 2022

  1. Slide 1: 2Q22 Regulation G Financial Reconciliations

    2Q22 Regulation G Financial Reconciliations 1 EVERY STEP OF THE WAY © 2022 Charles River Laboratories International, Inc.

  2. Slide 2: Reconciliation of GAAP to Non-GAAP Selected Business Segment Information

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) (1) (in thousands, except percentages) Three Months Ended Six Months Ended June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Research Models and Services Revenue

  3. Slide 3: Reconciliation of GAAP to Non-GAAP Selected Business Segment Information (continued)

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) (1) (in thousands, except percentages) CONTINUED FROM PREVIOUS SLIDE Three Months Ended Six Months Ended June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Unalloc

  4. Slide 4: Reconciliation of GAAP Earnings to Non-GAAP Earnings

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED) (1) (in thousands, except per share data) Three Months Ended Six Months Ended June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Net income attributable to common shareholders $ 109,3

  5. Slide 5: Reconciliation of GAAP Revenue Growth to Non-GAAP Organic Revenue Growth

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP REVENUE GROWTH TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) (1) Three Months Ended June 25, 2022 Total CRL RMS Segment DSA Segment MS Segment Revenue growth, reported 6.4 % 5.5 % 9.6 % (1.5) % Decrease due to foreign exchange 3

  6. Slide 6: Reconciliation of GAAP to Non-GAAP Revenue and EPS Guidance

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP REVENUE AND EARNINGS PER SHARE (EPS) Guidance for the Twelve Months Ended December 31, 2022E 2022 GUIDANCE CURRENT PRIOR Revenue growth, reported 9.0% - 11.0% 13.5%-15.5% Less: Contribution from acquisitions/divestitur

  7. Slide 7: Reconciliation of GAAP to Non-GAAP Net Interest Expense

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP NET INTEREST EXPENSE (1) (in thousands) Three Months Ended Fiscal Year Ended June 25, 2022 March 26, 2022 June 26, 2021 December 31, 2022E GAAP Interest expense, net $ 3,515 $ 16,019 $ 16,019 $75,000-$79,000 Exclude: W

  8. Slide 8: Reconciliation of Gross/Net Leverage Ratio, Including GAAP Net Income to Adjusted EBITDA

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GROSS/NET LEVERAGE RATIO, INCLUDING GAAP NET INCOME TO ADJUSTED EBITDA (1) (dollars in thousands, except for per share data) June 25 December 25, December 26, December 28, December 29, December 30, December 31, December 26, December 27

  9. Slide 9: Reconciliation of GAAP to Non-GAAP Selected Business Segment Information

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) (1) (in thousands, except percentages) Three Months Ended March 26, 2022 Unallocated Corporate Overhead $ (50,458) Add back: Severance 1,087 Acquisition related adjustm

  10. Slide 10: Reconciliation of GAAP Tax Rate to Non-GAAP Tax Rate

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TAX RATE TO NON-GAAP TAX RATE (UNAUDITED) (1) (in thousands) Three Months Ended Six Months Ended June 25, 2022 March 26, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Income before income taxes & noncontrolling interests $ 144,11

  11. Slide 11: Reconciliation of Free Cash Flow (Non-GAAP)

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF FREE CASH FLOW (NON-GAAP) (1) (in thousands) Three Months Ended Six Months Ended Fiscal Year Ended June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 December 31, 2022E Net cash provided by operating activities $ 149,474 $ 186,590

  12. Slide 12: © 2022 Charles River Laboratories International, Inc.

    © 2022 Charles River Laboratories International, Inc.

Charles River Laboratories International — Q2 2022 Earnings Presentation on 6ix